JTK-853
/ Japan Tobacco
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 20, 2019
Pharmacokinetics, Food Effect, Ketoconazole Interaction, and Safety of JTK-853, a Novel Nonnucleoside HCV Polymerase Inhibitor, After Ascending Single and Multiple Doses in Healthy Subjects.
(PubMed, Clin Pharmacol Drug Dev)
- "Trial simulation-based ratios (n = 1000/dose level) of trough JTK-853 plasma concentrations to the in vitro EC for HCV genotype 1b were assessed for dose selection in a separate proof-of-concept study in patients. The studies enabled delineation of key drug attributes for further assessments in the target population."
Clinical • Journal • PK/PD data • Hepatitis C Virus • Immunology • Infectious Disease
1 to 1
Of
1
Go to page
1